Omics approaches (transcriptomics and proteomics) have identified associations between COVID-19 and Alzheimer’s disease (AD) at transcription level as well as between infection-relevant proteins, cognitive deterioration, and brain volume loss, mainly in the temporal lobe, including plasma biomarkers which are hallmarks of AD dementia, such as phosphorylated tau-181 (p-Tau-181) and amyloid beta (Aβ42, Aβ42:40 ratio) [8,13,27,28], confirming the cross-talk between SARS-CoV-2 infection and the long-term risk of dementia [26]. The gene discussed is MAPT; the disease is COVID-19.